Razuprotafib is under clinical development by Aadi Bioscience and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Razuprotafib’s likelihood of approval (LoA) and phase transition for Diabetic Nephropathy took place on 21 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 21 May 2021 decreased Razuprotafib’s LoA and PTSR for Ocular Hypertension, and decreased LoA and PTSR for Open-Angle Glaucoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Razuprotafib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Razuprotafib overview
Razuprotafib is under development for the treatment of open-angle glaucoma, ocular hypertension, diabetic nephropathy. It is administered through subcutaneous route as injection and through ophthalmic route as eye drops. The drug candidate is a human protein tyrosine phosphotase beta (HPTP beta) inhibitor / angiopoietin 2 modulator specifically Tie-2 activator. HPTP beta is an enzyme together with protein-tyrosine kinase regulates tyrosine phosphorylation and dephosphorylation in cellular signal transduction and angiopoietin signaling. AKB-9778 was also under development for the treatment of melanoma and renal cancer. It was also under development for the treatment of diabetic macular edema, non-proliferative diabetic retinopathy, age-related macular degeneration, vascular leak syndrome, retinal vein occlusion, breast cancer and and acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Aadi Bioscience overview
Aadi Bioscience, formerly Aerpio Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that focused on the developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The company lead drug product, FYARROTM, (nab-sirolimus) is a form of sirolimus bound to albumin. It also focuswd on the drug discovery and development. The company’s FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa). The company serves patients in the United States. Aadi Bioscience is headquartered in Los Angeles, California, the US
Quick View Razuprotafib LOA Data
| Report Segments |
|
| Drug Name |
|
| Administration Pathway |
|
| Therapeutic Areas |
|
| Key Developers |
|
| Highest Development Stage |
|
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
